IPO Update: High-Flying Biopharma IPOs Average 77.1% Return Through Q2

 
• By Mandy Jackson
  
businessman hand holding dollar plane with IPO text ,business idea , business concept, analysis concept
High-flying IPO returns ranged from -33.1% for Ayala to +438.6% for Schrodinger • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business